Study of photosensitizers pharmacokinetics in mouse tumor model by transillumination fluorescence imaging in vivo

In this work we demonstrate an efficiency of transillumination fluorescence imaging for intravital study of photosensitizers pharmacokinetics in tumor-bearing mice. Experiments were performed on CBA mice with subcutaneously transplanted cervical carcinoma. Photosensitizer fotoditazin was used in the therapeutic dose of 10 mg/kg, i.v. Measuring the fluorescence in the whole tumors at different times after injection of photosensitizer, we obtained in vivo data about the drug accumulation and elimination. It was found in vivo that the period of maximum uptake of the photosensitizer in the mouse tumor is from 1 to 8 h post-injection, and its concentration in the tumor tissue at this time is about 2 μg/g. An accumulation of the photosensitizer in the tumor was confirmed by standard methods ex vivo. Noninvasive assessment of pharmacokinetics by transillumination imaging setup provides an opportunity for rapid and cost-effective studies of newly developed photosensitizers.

[1]  Andrei V. Reshetnickov,et al.  One more PDT application of chlorin e6 , 2000, BiOS.

[2]  Vasilis Ntziachristos,et al.  Transillumination fluorescence imaging in mice using biocompatible upconverting nanoparticles. , 2009, Optics letters.

[3]  Hamid Dehghani,et al.  Fluorescence tomography characterization for sub-surface imaging with protoporphyrin IX. , 2008, Optics express.

[4]  Andrei V. Reshetnickov,et al.  Novel drug form of chlorin e6 , 1999, Current Research on Laser Use in Oncology.

[5]  Michael R Hamblin,et al.  In vivo fluorescence imaging of the transport of charged chlorine6 conjugates in a rat orthotopic prostate tumour , 1999, British Journal of Cancer.

[6]  Eva M. Sevick-Muraca,et al.  Pharmacokinetics of ICG and HPPH-car for the Detection of Normal and Tumor Tissue Using Fluorescence, Near-infrared Reflectance Imaging: A Case Study¶ , 2000, Photochemistry and photobiology.

[7]  Gregory C. Burke,et al.  Comparison of Photosensitizer (AlPcS2) Quantification Techniques: In Situ Fluorescence Microsampling Versus Tissue Chemical Extraction¶ , 2001, Photochemistry and photobiology.

[8]  S. Hahn,et al.  Intraperitoneal photodynamic therapy. , 2007, Cancer treatment and research.

[9]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[10]  Zheng Huang,et al.  A Review of Progress in Clinical Photodynamic Therapy , 2005, Technology in cancer research & treatment.

[11]  C J Gomer,et al.  Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1990, Cancer research.

[12]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[13]  Thomas H Foster,et al.  In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. , 2008, Neoplasia.

[14]  C J Gomer,et al.  Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1992, Cancer research.

[15]  A. Uchida,et al.  Extracorporeal Photodynamic Image Detection of Mouse Osteosarcoma in Soft Tissues Utilizing Fluorovisualization Effect of Acridine Orange , 2007, Oncology.

[16]  Oleg V. Seliverstov,et al.  Clinical trials of a new chlorin photosensitizer for photodynamic therapy of malignant tumors , 2002, SPIE BiOS.

[17]  I. Turchin,et al.  OPTICAL TOMOGRAPHY: Spectrally resolved fluorescence diffuse tomography of biological tissues , 2010 .

[18]  M. L. Gelfond,et al.  PDT opportunities in oncology practice , 2005, Current Research on Laser Use in Oncology.

[19]  Vasilis Ntziachristos,et al.  Normalized Transillumination of Fluorescent Proteins in Small Animals , 2006, Molecular imaging.

[20]  H. Kato,et al.  In vivo fluorescence kinetics of mono-l-aspartyl chlorin e6 (NPe6) and influence of angiogenesis in fibrosarcoma-bearing mice , 1998, International Journal of Clinical Oncology.

[21]  Thomas Pongratz,et al.  ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. , 2007, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[22]  Rinaldo Cubeddu,et al.  In vivo absorption spectroscopy of tumor sensitizers with femtosecond white light. , 2005, Applied optics.

[23]  Giovanni Mettivier,et al.  In vivo macroscopic HPD fluorescence reflectance imaging on small animals bearing surface ARO/NPA tumor , 2005, European Conference on Biomedical Optics.

[24]  Hui Li,et al.  Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent. , 2007, Bioconjugate chemistry.

[25]  I. G. Meerovich,et al.  Fluorescence diffuse tomography for detection of red fluorescent protein expressed tumors in small animals. , 2008, Journal of biomedical optics.

[26]  C. Perotti,et al.  ALA and ALA hexyl ester induction of porphyrins after their systemic administration to tumour bearing mice , 2002, British Journal of Cancer.

[27]  Maurice C. G. Aalders,et al.  Photodetection with 5-Aminolevulinic Acid–induced Protoporphyrin IX in the Rat Abdominal Cavity: Drug-dose–dependent Fluorescence Kinetics¶ , 2000 .

[28]  Bryan Q. Spring,et al.  In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring , 2009, British Journal of Cancer.

[29]  Rui Hu,et al.  Intratumor administration of the photosensitizer pc 4 affords photodynamic therapy efficacy and selectivity at short drug-light intervals. , 2010, Translational oncology.

[30]  I. Turchin,et al.  In vivo study of photosensitizer pharmacokinetics by fluorescence transillumination imaging. , 2010, Journal of biomedical optics.